Melatonin in Patients With Multiple Sclerosis (MS).

NCT ID: NCT03498131

Last Updated: 2025-03-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-05-09
• Study Completion Date: 2023-12-11

Brief Summary

To date, there are no published data on the role of melatonin supplementation or the appropriate dose for patients with multiple sclerosis. Because of the potential benefits of melatonin, this pilot study will be an exploratory investigation to evaluate the effect of supplementing melatonin in subjects with multiple sclerosis who are taking an oral disease modifying therapy (DMT) for 6 months or longer. It is our intent that the results of this study will support the rationale and be a prelude to a larger trial which can focus on clinical efficacy of melatonin therapy outcomes.

Detailed Description

The primary objective of this study is to evaluate the change in 24 hour urinary 6-sulfatoxymelatonin (6SMT) collected for 24 hours in two twelve hour sessions. The secondary objectives are to evaluate the change in serum morning melatonin level. In addition, quality of life (QOL) measures will be assessed including the Modified Fatigue Impact Scale (MFIS), Multiple Sclerosis Impact Scale (MSIS-29), and the Pittsburgh Sleep Quality Index (PSQI). Clinical objectives include the number of relapses during the trial and a change in the Patient Determined Disease Steps (PDDS) & Performance Scales (PS).

The pilot study is a one-year randomized, rater- and dose-blinded trial evaluating the potential role of melatonin in subjects with relapsing multiple sclerosis who have been taking a stable dose of an oral disease modifying therapy (DMT) for at least 6 months. The oral DMTs include dimethyl fumarate, fingolimod, teriflunomide, diroximel fumarate, siponimod, and ozanimod. Thirty subjects with relapsing forms of multiple sclerosis who meet all of the eligibility criteria will be enrolled at Providence Neurological Specialties in Portland, Oregon.

Conditions

Relapsing Remitting Multiple Sclerosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

3 mg Melatonin

Subjects will receive 3 mg melatonin once a day.

Group Type: EXPERIMENTAL

3 mg Melatonin

Intervention Type: DRUG

3 mg melatonin once each day

5 mg Melatonin

Subjects will receive 5 mg melatonin once a day.

Group Type: EXPERIMENTAL

5 mg Melatonin

Intervention Type: DRUG

5 mg Melatonin once each day

Interventions

3 mg Melatonin

3 mg melatonin once each day

Intervention Type: DRUG

5 mg Melatonin

5 mg Melatonin once each day

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male and female subjects with relapsing forms of MS who have been on a stable dose of dimethyl fumarate, fingolimod, teriflunomide, diroximel fumarate, siponimod, or ozanimod for 6 months or longer
• Confirmed diagnosis of Relapsing MS
• Women of childbearing potential must employ proven methods to prevent pregnancy during the course of the trial; the acceptable method will be left to the judgment of the investigator
• Not pregnant or lactating
• No evidence of significant cognitive or psychiatric disorder
• Able to understand the purpose and risks of the study
• Must be willing to sign an informed consent and follow the protocol requirements

Exclusion Criteria

• Use of melatonin within 30 days of enrollment
• The addition of any sleep aide or change in dose within 30 days of enrollment or during the trial
• The addition or change in dose of Vitamin D within 30 days of enrollment or during the trial
• Change in DMT during the trial
• Steroid therapy within 30 days of enrollment
• Use of anticoagulation at the time of enrollment and during the trial
• The addition of an antidepressant is not allowed during the study period; if on an antidepressant at screening, the dose must be stable 30 days prior to enrollment and dose changes are prohibited during the study
• The addition or change in dose of any stimulants, including but not limited to, amantadine, armodafinil, methylphenidate, or modafinil within 30 days of enrollment or during the trial

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Providence Health & Services

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kyle Smoot, MD

Role: PRINCIPAL_INVESTIGATOR

Providence Health & Services

Locations

Providence MS Center

Portland, Oregon, United States

Countries

United States

References

Smoot K, Gervasi-Follmar T, Marginean H, Chen C, Cohan S. Impact of oral melatonin supplementation on urine and serum melatonin concentrations and quality-of-life measures in persons with relapsing multiple sclerosis. Mult Scler Relat Disord. 2024 Oct;90:105799. doi: 10.1016/j.msard.2024.105799. Epub 2024 Aug 3.

Reference Type: DERIVED

PMID: 39126937 (View on PubMed)

Ghareghani M, Farhadi Z, Rivest S, Zibara K. PDK4 Inhibition Ameliorates Melatonin Therapy by Modulating Cerebral Metabolism and Remyelination in an EAE Demyelinating Mouse Model of Multiple Sclerosis. Front Immunol. 2022 Mar 9;13:862316. doi: 10.3389/fimmu.2022.862316. eCollection 2022.

Reference Type: DERIVED

PMID: 35355991 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

https://oregon.providence.org/our-services/p/providence-brain-and-spine-institute/

Providence Brain and Spine Institute

Other Identifiers

2017000005

Identifier Type: -

Identifier Source: org_study_id